MINNEAPOLIS (April 10, 2017) – On Thursday, April 13, OneOme’s director of medical affairs Josiah Allen will speak about the power of pharmacogenomics in personalized medicine at the Design of Medical Devices Conference Emerging Technology Forum. The event, which explores “Personalized Medical Devices and Care," takes place from 10:15 a.m. to 11:45 a.m. at the Commons Hotel in Minneapolis.
Pharmacogenomics is an emerging field that combines the study of how drugs affect our bodies (pharmacology) with the study of our genes and their functions (genomics). Allen will share insights about how OneOme and pharmacogenomics can improve a patient’s response to his or her medications. He will also discuss the clinical and economic benefits of OneOme’s pharmacogenomic test and support system.
WHAT: OneOme participates in 2017 Design of Medical Devices Conference
Emerging Technology Forum "Personalized Medical Devices and Care"
WHERE: The Commons Hotel – Meridian Ballrooms
615 Washington Ave SE, Minneapolis, Minnesota
WHEN: Thursday, April 13, 2017
10:15 a.m.–11:45 a.m.
WHO: Josiah Allen, OneOme Director of Medical Affairs
Additional speakers from Boston Scientific Corp, University of Massachusetts Medical School, IBM Watson Health, Medical Device Innovation Consortium
Adverse drug reactions are the fourth leading cause of death in the United States. OneOme aims to address this crisis by helping physicians make better prescription decisions based on their patients’ unique DNA. The OneOme RightMed® pharmacogenomic test is an actionable, comprehensive test that helps personalize patients’ treatments, save time and money by eliminating the trial and error approach, reduce the risk of adverse drug reactions, and limit unintended drug-to-drug interactions.
Co-developed with Mayo Clinic, the RightMed test covers over 340 drugs and is offered at only $249. The test is physician-ordered and produces an easy-to-read report, which categorizes drugs based on the individual’s DNA.
Josiah Allen has significant experience in many aspects of personalized medicine, including clinical research, product development, and clinical adoption and implementation. Allen is an author of over a dozen peer-reviewed publications in pharmacogenomics, and he has lectured extensively on the clinical applications of pharmacogenomics. Prior to joining OneOme, Allen worked at the Mayo Clinic Department of Psychiatry and the Center for Individualized Medicine, and he was one of the founding members of Assurex Health. Allen earned his bachelor's degree in psychology from Wheaton College and completed graduate work in molecular genetics and pharmacology at the University of Cincinnati.
The Design of Medical Devices Conference is a four-day event that identifies itself as “the world’s largest premiere medical devices conference”. For more information about the session and the conference, please visit: dmd.umn.edu/2017/keynoteforum2.html.
The OneOme platform was co-developed and exclusively licensed from Mayo Clinic to bring pharmacogenomics into routine clinical care. OneOme is a privately held company backed by early-stage venture firm Invenshure, LLC, and Mayo Clinic. To learn more, visit oneome.com.